The EPS projection of Abbott Laboratories (NYSE:ABT) for quarter ended 2016-09-30 is $0.59. A week before, the EPS forecast was $0.59 against target of $0.59, a month earlier. This estimate stood at $0.59 60 days earlier versus forecast of $0.59 90 days earlier, confirming a deviation of 0%.
Abbott Laboratories (NYSE:ABT) reported that 18 days ago, the positive EPS revisions were 0 and negative revisions at 3.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 7, 7, 0 and 7, respectively.
The downgrade of EPS estimates for Abbott Laboratories (NYSE:ABT) in the preceding 120, 60, 30 and 90 days were 1, 1, 0 and 1, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of Abbott Laboratories (NYSE:ABT) was $0.59. This projection was computed after accounting 12 calls. As reported on 2016-04-20 the EPS was $0.41. The change was $0.02, demonstrating a percentage deviation of 5.13%. The projections confirmed a standard deviation of 0.01.
Quarterly Sales Estimates
For the fiscal 2018, the yearly sales target for Abbott Laboratories (NYSE:ABT) stands at $6112.1 and the median estimate at $6112.1. Almost 2 analysts announced their estimates.
The highest estimate is $6142 while the lowest target is $6082.2 showing standard deviation of 42.284%.
As many as 2 analysts released sales estimates reised in upside while 2 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 2 revised sales number projection on upside while 2 lowered the sales target, demonstrating a deviation of 0.491%.
A quarter ago, 2 hiked sales estimations and 2 reduced sales forecast. Abbott Laboratories (NYSE:ABT) stated that the change in forecast was 1.02%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...